Bellevue Group’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-9,500
Closed -$940K 225
2020
Q4
$940K Buy
+9,500
New +$1.16M 0.01% 156

Other funds holding LKFT

Bellevue Group's LKFT Position: Q1 2021 in Review

Bellevue Group sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q1 2021, closing a stake of 9,500 shares — an estimated $940K sold.

Bellevue Group first reported a position in LKFT in Q4 2020 and held it in 1 quarter. The position peaked at $940K in Q4 2020. 131 funds tracked by Wall St. Rank hold LKFT as of Q1 2021.

  • Bellevue Group reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q1 2021 after selling out during the quarter.
  • Bellevue Group sold 9,500 Lakefront Biotherapeutics American Depositary Shares shares in Q1 2021, an estimated $940K.
  • Bellevue Group first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q4 2020 and held it in 1 quarter.
  • Bellevue Group's Lakefront Biotherapeutics American Depositary Shares position peaked at $940K in Q4 2020.
  • 131 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2021.

Based on Bellevue Group's 13F filing for Q1 2021, filed 12 May 2021.